News

Seattle Children's Aims to Outsmart Cancer in a New Trial

Seattle Children's Aims to Outsmart Cancer in a New Trial

Seattle Children's Ben Towne Center for Childhood Cancer Research is actively fighting pediatric leukemia by harvesting and reprogramming a child's own T cells and using the immune system to fight cancer. Those T cells are collected from the patient and re-engineered into targeted cancer-killing CAR-T cells. “We've achieved phenomenal remission rates. With that therapy more than 90% of our kids have gotten into remission. These are kids that were resistant to traditional chemotherapy,” said Seattle Children’s oncologist Dr. Colleen Annesley.

About Seattle Children’s

Seattle Children’s mission is to provide hope, care and cures to help every child live the healthiest and most fulfilling life possible. Together, Seattle Children’s Hospital, Research Institute and Foundation deliver superior patient care, identify new discoveries and treatments through pediatric research, and raise funds to create better futures for patients.

Ranked as one of the top children’s hospitals in the country by U.S. News & World Report, Seattle Children’s serves as the pediatric and adolescent academic medical center for Washington, Alaska, Montana and Idaho – the largest region of any children’s hospital in the country. As one of the nation’s top five pediatric research centers, Seattle Children’s Research Institute is internationally recognized for its work in neurosciences, immunology, cancer, infectious disease, injury prevention and much more. Seattle Children’s Hospital and Research Foundation works with the Seattle Children’s Guild Association, the largest all-volunteer fundraising network for any hospital in the country, to gather community support and raise funds for uncompensated care and research. Join Seattle Children’s bold initiative – It Starts With Yes: The Campaign for Seattle Children’s – to transform children’s health for generations to come.

For more information, visit seattlechildrens.org or follow us on Twitter, Facebook, Instagram or on our On the Pulse blog.